Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | GPR183 | P32249 | 7/20 | 0.73 |
| ▸ | ACHE | P22303 | 2/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | FAAH | O00519 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17938752 | 1.00 | MEN1 (0.78) | MEN1KMT2AGPR183ACHEL3MBTL1 | |
| SCHEMBL3159223 | 0.90 | MEN1 (0.85) | MEN1KMT2AGPR183ACHEL3MBTL1 | |
| SCHEMBL5707169 | 0.90 | MEN1 (0.85) | MEN1KMT2AGPR183ACHEL3MBTL1 | |
| SCHEMBL17938698 | 0.88 | GPR183 (0.93) | MEN1KMT2AGPR183L3MBTL1 | |
| SCHEMBL17938699 | 0.88 | GPR183 (0.93) | MEN1KMT2AGPR183L3MBTL1 | |
| SCHEMBL16598998 | 0.87 | MEN1 (0.68) | MEN1KMT2AGPR183ACHEL3MBTL1 | |
| SCHEMBL16598995 | 0.87 | MEN1 (0.68) | MEN1KMT2AGPR183ACHEL3MBTL1 | |
| SCHEMBL2906086 | 0.86 | F2R (0.72) | MEN1KMT2AGPR183ACHEL3MBTL1 | |
| SCHEMBL17938651 | 0.86 | GPR183 (0.81) | MEN1KMT2AGPR183ACHEL3MBTL1 | |
| SCHEMBL17938649 | 0.86 | GPR183 (0.81) | MEN1KMT2AGPR183ACHEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776979-B2 | EBI2 modulators | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-03 | — | — | US | claimed |
| US-9776979-B2 | EBI2 modulators | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776979-B2 | EBI2 modulators | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160214951-A1 | EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214951-A1 | EBI2 MODULATORS | BIRC2, HAVCR2, MAVS | MEN1 2201/4885KMT2A 1057/4885GPR183 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.